India's Cipla breaks into vaccines with Serum deal in Europe

Indian generics maker Cipla is taking its low-cost game into the vaccine field, thanks to a new deal with the Serum Institute of India (SII).

Cipla CEO Subhanu Saxena

Under the agreement, Cipla--India's fourth-largest drugmaker--will be responsible for seeking EMA approval and marketing green-lighted SII-produced vaccines in Europe.

For affordability-focused Serum, the tie-up is the "perfect platform" for bringing low-cost vaccines to the continent, the institute's CEO, Adar Poonawalla, said in a statement. "Cipla and SII share the same core values such as self-sufficiency, affordability, accessibility, quality and commitment to global health," Cipla CEO Subhanu Saxena added.

Cipla European head Frank Pieters

The pact will also help Cipla strengthen its European footprint, which has been growing over the past 6 months as the company rolled out Salmeterol/Fluticasone, its generic of GlaxoSmithKline's ($GSK) respiratory behemoth Advair, in countries like Germany, Sweden, the Czech Republic, Slovakia and Croatia. In the year ended March 2013, the region kicked in 5.7% of the company's total revenue, Reuters notes.

And as Cipla works to offer "a new pharma concept built on layers of value," it sees vaccines as "one of the critical components of our offering to European patients," European head Frank Pieters said in a statement.

"With Cipla's front-end presence and with the support of a dedicated sales force, we will broaden the reach of vaccines across Europe," he said.

- read Cipla's release
- get more from Reuters

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

Pfizer's shot will go before an FDA expert panel on Dec. 10, with Moderna's review pegged for the 17th, Warp Speed chief Moncef Slaoui, Ph.D., said.